Cocrystal Pharma (COCP) EBIT Margin (2010 - 2026)

Cocrystal Pharma (COCP) reported EBIT Margin of 1047.11% for Q1 2026, down 264.27% sequentially from 287.45% in Q4 2020.

Cocrystal Pharma (COCP) EBIT Margin (2010 - 2026) Analysis & Trends

Cocrystal Pharma (COCP) has 8 years of EBIT Margin data on file, last reported at 1047.11% in Q1 2026.

For the quarter ending Q1 2026, EBIT Margin changed N/A year-over-year to 1047.11%; the trailing twelve-month figure through Mar 2026 stood at 508.1% (changed N/A YoY), and the FY2020 full-year result was 475.97%, up 26148.0% from the prior year.
EBIT Margin declined to 1047.11% in Q1 2026, from 287.45% in the prior quarter.
In the past five years, EBIT Margin ranged from a high of 1047.11% in Q1 2026 to a low of 1047.11% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	16.51%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	17.83%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Cocrystal Pharma	12.57 Mn	7.74 Mn	-	-1,047.11%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-1,047.11%
Dec 31, 2020	-287.45%
Sep 30, 2020	-553.99%
Jun 30, 2020	-622.74%
Mar 31, 2020	-425.38%
Dec 31, 2019	-11,921.64%
Sep 30, 2019	-367.48%
Jun 30, 2019	-261.82%
Mar 31, 2019	56.66%
Sep 30, 2015	-14,958.33%
Jun 30, 2015	-14,137.04%
Mar 31, 2015	-8,029.63%
Jun 30, 2013	-37.85%
Mar 31, 2013	-50.27%
Dec 31, 2012	-64.08%
Sep 30, 2012	6.92%
Jun 30, 2012	5.35%
Mar 31, 2012	-16.85%
Dec 31, 2011	-21.30%
Sep 30, 2011	-56.39%